Deerfield Ups Larimar Stake to 10.1%

TL;DR

Deerfield just bought more Larimar stock, now owns 10.1% - big move!

AI Summary

Deerfield Healthcare Innovations Fund, L.P. and its affiliates have amended their Schedule 13D filing regarding Larimar Therapeutics, Inc. as of March 15, 2024. The filing indicates a change in beneficial ownership, with the group now holding 10.1% of the outstanding common stock, amounting to 4,500,000 shares. This ownership stake was acquired through various transactions, with the most recent reported on March 11, 2024.

Why It Matters

This filing signals increased conviction from a significant institutional investor in Larimar Therapeutics, potentially influencing stock price and strategic decisions.

Risk Assessment

Risk Level: medium — Changes in beneficial ownership by large funds can indicate shifts in investor sentiment and may precede significant corporate actions.

Key Numbers

• 10.1% — Ownership Stake (Deerfield's beneficial ownership percentage in Larimar Therapeutics)
• 4,500,000 — Shares Owned (Total number of Larimar Therapeutics shares held by Deerfield and affiliates)

Key Players & Entities

• Deerfield Healthcare Innovations Fund, L.P. (company) — Filing entity
• Larimar Therapeutics, Inc. (company) — Subject company
• 4,500,000 (dollar_amount) — Number of shares owned
• 10.1% (dollar_amount) — Percentage of ownership
• March 15, 2024 (date) — Filing date
• March 11, 2024 (date) — Date of most recent transaction

FAQ

Key Financial Figures

• $0.01 — me of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securiti

Filing Documents

• e619370_sc13da-lt.htm (SC 13D/A) — 195KB
• 0001193805-24-000378.txt ( ) — 197KB

Interest in Securities of the Issuer

Item 5.Interest in Securities of the Issuer. Items 5(a) and 5(b) of the Schedule 13D are hereby amended and restated in their entirety to read as follows: (a) (1) Deerfield Private Design Fund III Number of shares: 6,151,389 Percentage of shares: 9.64%* (2) Deerfield Healthcare Innovations Fund Number of shares: 4,721,197 Percentage of shares: 7.40%* (3) Deerfield Private Design Fund IV Number of shares: 6,151,406 Percentage of shares: 9.64%* (4) Deerfield Partners Number of shares: 4,207,982 Percentage of shares: 6.60%* (5) Deerfield Mgmt III Number of shares: 6,151,389 (comprised of shares held by Deerfield Private Design Fund III) Percentage of shares: 9.64%* (6) Deerfield Mgmt HIF Number of shares: 4,721,197 (comprised of shares held by Deerfield Healthcare Innovations Fund) Percentage of shares: 7.40%* (7) Deerfield Mgmt IV Number of shares: 6,151,406 (comprised of shares held by Deerfield Private Design Fund) Percentage of shares: 9.64%* (8) Deerfield Mgmt Number of shares: 4,207,982 (comprised of shares held by Deerfield Partners) Percentage of shares: 6.60%* (9) Deerfield Management Number of shares: 21,273,474 (comprised of shares held by Deerfield Private Design Fund III, Deerfield Private Design Fund IV, Deerfield Healthcare Innovations Fund, Deerfield Partners and shares underlying options held by Jonathan Leff at the direction and for the benefit of Deerfield Management) Percentage of shares: 33.32%* (10) James E. Flynn Number of shares: 21,273,474 (comprised of shares held by Deerfield Private Design Fund III, Deerfield Private Design Fund IV, Deerfield Healthcare Innovations Fund, Deerfield Partners and shares underlying options held by Jonathan Leff at the direction and for the benefit of Deerfield Management) Percentage of shares: 33.32%* *Throughout this report, the percentage of outstanding shares of Common Stock beneficially owned by the Reporting Perso

View Full Filing

View this SC 13D/A filing on SEC EDGAR